anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains pertinent genetic, health, and biological samples such as blood derived from a large-scale population. Researchers may use disease correlates and predictors identified from the genetic, health, and personal information contained in the Biobank as a resource to investigate cardiovascular disease, hypertension, diabetes, and a myriad of other disorders. Through these studies, researchers may identify the progression of risk factors in certain diseases and help develop novel strategies to detect, treat, or prevent such diseases. In addition, the Biobank serves as a valuable tool to assess how certain treatments may respond differently to individuals as a result of genotypic differences.

The investigators have demonstrated that lower natriuretic peptide (NP) levels are associated with a decreased insulin sensitivity and have a causal role in the development of diabetes and have also shown that certain populations, such as African Americans, have relatively low NP levels, which may contribute to their underlying risk for insulin resistance. Since NPs play an important role in the regulation of insulin sensitivity, one can infer that relatively low NP levels are an important biological contributor to the high prevalence rates of cardiometabolic disease in African Americans. The Biobank will contain genetic information concerning the presence of gene variants that encode NPs.
Non-naturally occurring polypeptide (I) is claimed, whose aminoacid sequence is similar enough to naturally-occurring stem cell factor (SCF) to give it the same haematopoietic biological activity. (I) is produced by eukaryotic or prokaryotic expression of an exogeneous DNA sequence, and has in vivo and in vitro biological activity. Also claimed are a DNA sequence encoding (I), a host transformed with the DNA sequence, a process for producing and recoverng SCF, a DNA sequence encoding a human SCF analogue, an antibody that binds SCF, a compsn.; of (I) with a water-soluble polymer, a method of preparing the above compsn. and a method of transfecting early haematopoietic stem cells. Routes of administration are e.g. parenteral, pulmonary, nasal and oral.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to inhalation preparation comprising dry powder-like composition containing formoterol and substance-carrier as the finely ground form. The filled volume density of the preparation is from 0.28 to 0.38 g/ml which can be used for treatment of patients with respiratory disorders. Invention relates to also method of preparing the composition and to method of treatment of patients suffering with respiratory disorder. EFFECT: improved dispersed property of drug. 7 cl, 2 ex
The invention relates to linum usitatissimum Linn. health-care wine for treating psoriasis. The linum usitatissimum Linn. health-care wine for treating psoriasis is prepared by performing impurity clearing on 23 g of linum usitatissimum Linn., 17 g of saposhnikovia divaricata, 18 g of fallopia multiflora, 16 g of cortex acanthopanacis and 19 g of asarum herb, mixing with 4000 g of kaoliang spirit at normal temperature, placing the above mixture in a conventional reaction kettle with a pressure of 0.4 Pa for 2-3 h and performing separation, adding 250 g of honey into the separated liquid, blending and performing clarification processing. The linum usitatissimum Linn. health-care wine for treating psoriasis. is simple and practicable in technological process, fresh and sweet in mouthfeel and good in effect, has the efficacy of clearing heat, cooling blood, activating blood and resolving stasis, and can help patients to activate blood, resolve stasis, improve physical quality from interior to exterior and reduce pain and inconvenience caused by psoriasis after drank for a long time.
Automated segmentation tools often encounter accuracy and adaptability issues when applied to images of different pathology. The purpose of this study is to explore the feasibility of building a workflow to efficiently route images to specifically trained segmentation models. By implementing a deep learning classifier to automatically classify the images and route them to appropriate segmentation models, we hope that our workflow can segment the images with different pathology accurately. The data we used in this study are 350 CT images from patients affected by polycystic liver disease and 350 CT images from patients presenting with liver metastases from colorectal cancer. All images had the liver manually segmented by trained imaging analysts. Our proposed adaptive segmentation workflow achieved a statistically significant improvement for the task of total liver segmentation compared to the generic single-segmentation model (non-parametric Wilcoxon signed rank test, n = 100, p-value << 0.001). This approach is applicable in a wide range of scenarios and should prove useful in clinical implementations of segmentation pipelines.
We prospectively compared clinical and biological parameters in ICU- and non-ICU-admitted Covid-19 patients, ICU-admitted patients with septic shock unrelated to Covid-19 and matched control subjects.

Primary hemostasis and coagulation parameters and endothelial biomarkers are measured. Activation of the renin-angiotensin-aldosterone system is monitored through measurements of plasma renin, angiotensin II, aldosterone, and serum soluble angiotensin-converting enzyme 2. Vascular oxidative status is assessed by measuring plasma lipids peroxides. Neutrophilic polymorphonuclear activation is assessed by measuring plasma levels of Triggering receptor expressed on myeloid cells-1. Vascular nitric oxide bioavailability is measured by quantification of the concentration of heme-nitrosylated hemoglobin (HbNO) in venous erythrocytes using Electron Paramagnetic Resonance spectroscopy. Structural abnormalities of vascular endothelial cells were analyzed by Transmission Electron- and Scanning Electron Microscopy.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic for infrared protection having improved protection unevenness of infrared reflecting effects after coating without uneven application during coating of the cosmetic.  <P>SOLUTION: The cosmetic is obtained by including (1) hollow resin spherical powder which may be coated with a metal oxide and (2) boron nitride powder. The hollow resin spherical powder which may be coated with the metal oxide preferably consists essentially of polyacrylonitrile and may be coated with the metal oxide. Titanium dioxide is preferably used as the metal oxide for coating in the hollow resin spherical powder which may be coated with the metal oxide. The average particle diameter of the hollow resin spherical powder is preferably 10-30 μm and preferably for the protection from infrared rays.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
MicroRNAs (miRNAs) are critical post-transcriptional gene regulators and their involvement in sporadic colon cancer (CRC) tumorigenesis has been confirmed. In this study we investigated differences in miRNA expression in microsatellite stable (MSS/EMAST-S), microsatellite unstable marked by high elevated microsatellite alterations at selected tetranucleotide repeats (MSS/EMAST-H), and high microsatellite unstable (MSI-H/EMAST-H) tumor subgroups as well as in tumors with different clinicopathologic characteristics. An RT-qPCR analysis of miRNA expression was carried out on 45 colon cancer and adjacent normal tissue samples (15 of each group). Overall, we found three differentially expressed miRNAs between the subgroups. miR-92a-3p and miR-224-5p were significantly downregulated in MSI-H/EMAST-H tumors in comparison to other subgroups. miR-518c-3p was significantly upregulated in MSS/EMAST-H tumors in comparison to stable and highly unstable tumors. Furthermore, we showed that miR-143-3p and miR-145-5p were downregulated in tumors in comparison to normal tissues in all subgroups. In addition, we showed overexpression of miR-125b-5p in well-differentiated tumors and miR-451a in less advanced tumors. This is the first report on differences in miRNA expression profiles between MSS/EMAST-S, MSS/EMAST-H, and MSI-H/EMAST-H colorectal cancers. Our findings indicate that the miRNA expression signatures differ in CRC subgroups based on their instability status.
A preventive and predictive healthcare platform is provided. This preventive and predictive healthcare platform includes a computer server connected to an electronic communication network. The server has a democratized data store that is owned by the platform user and acts as the single repository of all health information for the platform user (vital signs, medication, wellness profiles, etc.). This data store may be enabled on mobile devices such as smart phones and tablet computers. The server is configured to send and receive healthcare data to healthcare data providers, to process the healthcare data, and to transmit at least some of the healthcare data to one or more users. The preventive and predictive healthcare platform also has an artificial intelligence engine that includes a machine-based learning algorithm which provides a predictive and preventative care model for a platform user.
Cancer cachexia, a multi-organ disorder resulting from tumor and immune system interactions, prominently features muscle wasting and affects the survival of patients with cancer. Ursolic acid (UA) is known for its antioxidant, anti-inflammatory, and anticancer properties. However, its impact on cancer cachexia remains unexplored. This study aimed to assess the efficacy of UA in addressing muscle atrophy and organ dysfunction in cancer cachexia and reveal the mechanisms involved. UA dose-dependently ameliorated C2C12 myotube atrophy. Mechanistically, it inhibited the expression of muscle-specific RING finger containing protein 1 (MURF1) and the phosphorylation of signal transducer and activator of transcription 3 (STAT3), and upregulated the mRNA or protein levels of myogenic differentiation antigen and myogenin in cultured C2C12 myotubes treated with conditioned medium. In vivo, UA protected CT26 tumor-bearing mice against loss of body weight, as well as increased skeletal muscle and epididymal fat without affecting tumor growth. Additionally, UA increased food intake in CT26 tumor-bearing mice. The mRNA expression of tumor necrosis-α and interleukin 6 was significantly downregulated in the intestine, gastrocnemius, and heart tissues following 38 d UA administration. UA treatment reversed the levels of myocardial function indicators, including creatine kinase, creatine kinase-MB, lactate dehydrogenase, car-dial troponin T, and glutathione. Finally, UA treatment significantly inhibited the expression of MURF1, the phosphorylation of nuclear factor kappa-B p65, and STAT3 in the gastrocnemius muscle and heart tissues of cachexic mice. Our findings suggest that UA is a promising natural compound for developing dietary supplements for cancer cachexia therapy owing to its anti-catabolic effects.
The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game "Your Shape Fitness evolved". This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity).
PROBLEM TO BE SOLVED: To obtain a new carbapenem ester derivative exhibiting pharmacokinetics with excellent absorbing property and persistency when administered to organisms and useful as an active ingredient for medicines for treating bacterial infectious diseases due to various kinds of pathogenic bacteria by modifying hydroxyl group of hydroxyethyl group at a specific position of carbapenem skeleton with a group hydrolyzed in vivo. SOLUTION: This compound is represented by formula I [R1 is a group of formula II to formula IV (R4 and R5 are each H, a 1-4C alkyl or the like) or the like, R2 is H, a 1-10C alkoxycarbonyloxy-1-4C alkyl or the like; R3 is a 1-20C alkanoyl or the like], e.g. pivaloyloxymethyl 6-(1-acetoxyethyl)-1- methyl-2-(2-oxo-4-pyrrolidinylthio)-1-carbapen-2-em-3-carboxylate. The compound of formula I is obtained by reacting a compound of formula V with a reactive derivative of R3 (e.g. an alkoxycarbonyl halide) in a solvent (e.g. xylene) in the presence of a base (e.g. pyridine), preferably at -10 to 50 deg.C for 10 min to 10 hr.
The invention discloses an application of tea tree oil in treatment of animal bacterial pneumonia. An in vitro and vivo anti-bacterial experiment proves that the tea tree oil and a tea tree oil composition are strong in anti-bacterial effects and especially are strong in killing effects on fungus so that the tea tree oil and the tea tree oil composition are good in treatment effects on the animal bacterial pneumonia. In a sealed or semi-sealed environment, an effective concentration of the tea tree oil in air is achieved through atomization and the treatment effects can be achieved through normal breath of animals without individual dosing to every animal. The tea tree oil and the tea tree oil composition are convenient to dose, is high in efficiency, is suitable for a large-scale animal breeding field. Atomized tea tree oil not only can treat the animal bacterial pneumonia but also has a sterilization and disinfection effect on environmental. The application has a quite high practical application value.
Participants are allowed to complete CM three times per week for the maximum of 12-weeks. At the six- and 12-week time points, participants will complete the Treatment Effectiveness Assessment (TEA) with study personnel.
Metabolic dysfunction-associated steatotic liver disease (MASLD) occurs in subjects with obesity and metabolic syndrome. MASLD may progress from simple steatosis (i.e., hepatic steatosis) to steatohepatitis, characterized by inflammatory changes and liver cell damage, substantially increasing mortality. Lifestyle measures associated with weight loss and/or appropriate diet help reduce liver fat accumulation, thereby potentially limiting progression to steatohepatitis. As for diet, both total energy and macronutrient composition significantly influence the liver's fat content. For example, the type of dietary fatty acids can affect the metabolism of lipids and hence their tissue accumulation, with saturated fatty acids having a greater ability to promote fat storage in the liver than polyunsaturated ones. In particular, polyunsaturated fatty acids of n-3 series (omega-3), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have been intensively studied for their antisteatotic effects, both in preclinical animal models of obesity and hepatic steatosis and in overweight/obese patients. Their effects may depend not only on the dose and duration of administration of omega-3, or DHA/EPA ratio, but also on the lipid class used for their supplementation. This review summarizes the available evidence from recent comparative studies using omega-3 supplementation via different lipid classes. Albeit the evidence is mainly limited to preclinical studies, it suggests that phospholipids and possibly wax esters could provide greater efficacy against MASLD compared to traditional chemical forms of omega-3 supplementation (i.e., triacylglycerols, ethyl esters). This cannot be attributed solely to improved EPA and/or DHA bioavailability, but other mechanisms may be involved. Keywords: MASLD • Metabolic dysfunction-associated steatotic liver disease • NAFLD • Non-alcoholic fatty liver disease • n-3 polyunsaturated fatty acids.
This a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial to assess the efficacy and safety of camrelizumab combination with apatinib and eribulin in female patients age of 18 to 70 with advanced TNBC, and previously treated with at least one line of systemic therapy in the advanced setting. Prior therapy (adjuvant/neoadjuvant/advanced) must have included an anthracycline and a taxane. The number of patients to be included is 46 patients (Simons two stage design). The primary objective is to assess the overall response rate (ORR). All enrolled patients will be treated with camrelizumab 200mg (iv. 3mg/kg for patient whose weight is below 50kg) on day 1 of each 21-day cycle, and apatinib 250mg daily (po, d1-d21), in combination with eribulin mesylate at 1.4 mg/m2 (iv.) on day 1 and day 8 of every 21-day cycle.
Use of the transcription factor SOX9, or a nucleic acid that encodes it, for treatment of cancers that express the carcinoembryonal antigen (CEA), other than breast cancers that are sensitive to retinoic acid receptor antagonists, is new. ACTIVITY : Cytostatic. MECHANISM OF ACTION : Gene therapy. The clone HT29CI16E, a derivative of the HT29 human intestinal adenocarcinoma cell line that expressed carcino-embryonal antigen (CEA), was transfected with (a) pcDNA6/TR, for expression of the tetracycline repressor and (b) pcDNA4/TO, containing the SOX9 sequence linked to the flag epitope and under control of a doxycycline (Dox)-inducible promoter. One of the clones produced by transfection was grown for 5 days (non-confluent) and then for 23 hours (confluent) in presence or absence of Dox, and the amounts of SOX9 and CEA measured. SOX9 was expressed only in presence of Dox and in this case CEA could not be detected, although it was detected in cell not treated with Dox (i.e. cells without SOX9). Proliferation of the cells of this clone was reduced by about 40% in presence of Dox and a significant increase in the number of apoptotic cells was observed in the presence of Dox compared with cells cultured in the absence of Dox.
Capsule or pill having a coating which is soluble in saliva, has an agreeable taste and stimulates the salivary glands. The capsules etc. are readily absorbed under difficult conditions e.g. while in an aeroplane or car, and are acceptable to children. The capsules are esp. of gelatin. A suitable coating compsn. for a single capsule comprises: 454.8 mg. sugar, 12 mg. syrup, 10.8 mg. citric acid, 1.5 mg. perfume, 0.9 mg. dye.
PURPOSE:To provide an orally administrable O/W-type emulsion obtained by dispersing an oily phase containing eicosapentaenoic acid (EPA) in an aqueous phase, having improved stability of the EPA, and useful for the prevention and remedy of arteriosclerosis and thrombosis. CONSTITUTION:An eicosapolyenoic acid (e.g. eicosapentaenoic acid or eicosahexaenoic acid) or its derivative such as ester, amide, etc. (collectively called as EPA) is used as the oily phase component, and is emulsified with an emulsifier such as phospholipid (preferably derived from cow's milk), a nonionic surface active agent, etc. The content of each component in the emulsion is, 1-40% (W/V), preferably 5-20% EPA, and 0.1-5% phospholipid or 0.1-10% nonionic surface active agent. The emulsifier is preferably a phospholipid for the better stabilization of EPA. The agent may be incorporated with 0.01-30% vitamin E which is an antioxidant and is expected to have the same drug action as EPA (0.1-1% vitamin E is sufficient to develop the antioxidant action).
Neurocritical patients (NCPs) in the intensive care unit (ICU) rapidly progress to respiratory and peripheral muscle dysfunctions, which significantly impact morbidity and death. Early mobilization in NCPs to decrease the incidence of ICU-acquired weakness has been showing rapid growth, although pertinent literature is still scarce. With this review, we summarize and discuss current concepts in early mobilization of critically ill patients within the context of neurologic pathology in NCPs. A narrative synthesis of literature was undertaken trying to answer the following questions: How do the respiratory and musculoskeletal systems in NCPs behave? Which metabolic biomarkers influence physiological responses in NCPs? Which considerations should be taken when prescribing exercises in neurocritically ill patients? The present review detected safety, feasibility, and beneficial response for early mobilization in NCPs, given successes in other critically ill populations and many smaller intervention trials in neurocritical care. However, precautions should be taken to elect the patient for early care, as well as monitoring signs that indicate interruption for intervention, as worse outcomes were associated with very early mobilization in acute stroke trials.
The impact of continued cigarette usage is profoundly felt not only upon the primary smoker, but also among children where SHSe is linked with asthma exacerbations. Children with caregivers who are active smokers are more likely to utilize acute healthcare resources and miss more days of school due to asthma symptoms. Issues of pediatric smoke exposure are notably higher among low-income populations. This particular group has a greater amount of financial strain that increases their desire to cease smoking but is among the least successful at accomplishing this task. Aggressive marketing campaigns by cigarette companies have specifically targeted the urban poor but similar techniques by public health officials, though on a much diminished scale, have yet to completely counter the hold that this addictive product has on members of lower socioeconomic status. One approach that has demonstrated efficacy in reducing smoking in resistant populations emphasizes financial incentives. Incentives may provide a substitute for the gratification derived from nicotine if they are properly structured. This proposal applies a contingency management schema among caregivers of pediatric asthmatics and a member of their caregiver's social network - both of whom are likely major contributors to the child's total secondhand smoke exposure. A pilot two-arm randomized-control trial will be employed over a 6-month time interval.The study population will consist of the primary caregiver and a selected member of their social network, both of who are known active smokers, and contemplating smoking cessation; both individuals spend time (either indoors or outdoors) with the asthmatic child. We will recruit 50 caregiver-child-social network triads among a population of children diagnosed with uncontrolled, persistent asthma and routinely exposed to high levels of SHSe. Caregivers and members of their social network who are both active smokers will be randomized to receive standard smoking cessation strategies (n=25 triads) with or without financial incentives (n=25 triads). SHSe will be measured directly using salivary cotinine levels from children and home air nicotine levels. Caregiver and social network member smoking behaviors will be measured by nicotine biomarkers; both test results will be the basis for incentive payments. Asthma control will be evaluated using validated questionnaires and review of the participant's electronic health record.
The invention discloses an anti-CD3/anti-CD19 dual-specific antibody and an application thereof. The anti-CD3/anti-CD19 dual-specific antibody comprises the combined structural domain of a completely-humanized anti-CD3 single-chain antibody and a completely-humanized anti-CD19 single-chain antibody. The variable region amino acid sequence of heavy chains and light chains of the completely-humanized anti-CD3 single-chain antibody is shown as the SEQ ID NO:7-8. The variable region amino acid sequence of heavy chains and light chains of the completely-humanized anti-CD19 single-chain antibody is shown as the SEQ ID NO:15-16. The anti-CD3/anti-CD19 dual-specific antibody has high affinity to CD3 molecules and CD19 molecules, and has the effect of conducting mediated activation on T lymphocytes to kill tumor cells. Moreover, the heavy chains and the light chains of the antibody molecules are completely humanized, and thus plenty of side effects are avoided.